Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.

Gain Therapeutics (NASDAQ: GANX) reported a Q4 loss of $(0.11) per share, surpassing the analyst consensus estimate of $(0.17) by 35.29%. This result is consistent with the company's performance during the same period last year.